Press Release: Information on the total number of voting rights |

Negma Group has transformed 120 Convertible bonds in Oxurion resulting in a EUR 300000 capital increase. This is part of Negma Group’s €30 million capital commitment¹ This will allow Oxurion to focus on advancing its novel and differentiated fundus drug Candidate targeting potential market opportunities in excess of USD 5 Billion.

Leuven, BELGIUM, Boston, MA, USA – November 4th, 2022 – 07.00 PM CET – Pursuant to Article 15 of the Belgian law of 2 May 2007 on the disclosure of significant holdings in issuers whose shares are admitted to trading on a regulated market and on various provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”) announces the information below following the issuance of 15,000,000 new ordinary shares on November 2, 2022 for a total amount of EUR 300,000 as a result of the conversion of 120 convertible bonds of the class B according to the capital commitment entered into with Negma Group.